TRCT
AQST icon

Tower Research Capital (TRC)’s Aquestive Therapeutics AQST Stock Holding History

Tower Research Capital (TRC)’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.1K Buy
9,170
+679
+8% +$2.86K ﹤0.01% 2965
2026
Q1 		$35.2K Buy
8,491
+2,481
+41% +$10.1K ﹤0.01% 3043
2025
Q4 		$38.8K Buy
6,010
+1,339
+29% +$8.34K ﹤0.01% 2620
2025
Q3 		$26.1K Sell
4,671
-1,345
-22% -$5.82K ﹤0.01% 3067
2025
Q2 		$19.9K Buy
6,016
+3,101
+106% +$8.89K ﹤0.01% 3682
2025
Q1 		$8.45K Sell
2,915
-1,024
-26% -$3.1K ﹤0.01% 3890
2024
Q4 		$14K Sell
3,939
-5,711
-59% -$26.3K ﹤0.01% 3484
2024
Q3 		$48.1K Buy
9,650
+7,050
+271% +$27.4K ﹤0.01% 2741
2024
Q2 		$6.76K Sell
2,600
-26,593
-91% -$88.8K ﹤0.01% 4543
2024
Q1 		$124K Buy
29,193
+24,837
+570% +$82.7K ﹤0.01% 1711
2023
Q4 		$8.8K Sell
4,356
-6,517
-60% -$11.5K ﹤0.01% 4462
2023
Q3 		$16.6K Sell
10,873
-3,889
-26% -$6.69K ﹤0.01% 3540
2023
Q2 		$24.4K Buy
14,762
+5,480
+59% +$9.91K ﹤0.01% 3206
2023
Q1 		$11K Buy
9,282
+4,287
+86% +$3.71K ﹤0.01% 4178
2022
Q4 		$5K Sell
4,995
-29,880
-86% -$28.1K ﹤0.01% 4828
2022
Q3 		$41K Sell
34,875
-3,264
-9% -$3.69K ﹤0.01% 3334
2022
Q2 		$24K Buy
38,139
+13,112
+52% +$17.4K ﹤0.01% 3589
2022
Q1 		$65K Buy
25,027
+23,239
+1,300% +$67.9K ﹤0.01% 2516
2021
Q4 		$7K Buy
+1,788
New +$8.97K ﹤0.01% 4887
2021
Q2 		– Sell
-12,044
Closed -$62K – 5446
2021
Q1 		$62K Buy
12,044
+7,547
+168% +$40.1K ﹤0.01% 2938
2020
Q4 		$24K Sell
4,497
-14,424
-76% -$86.4K ﹤0.01% 3742
2020
Q3 		$92K Buy
18,921
+17,938
+1,825% +$117K ﹤0.01% 3202
2020
Q2 		$5K Sell
983
-20,639
-95% -$95K ﹤0.01% 4258
2020
Q1 		$47K Buy
21,622
+8,172
+61% +$31.1K ﹤0.01% 1314
2019
Q4 		$78K Sell
13,450
-16,086
-54% -$83.7K 0.01% 1084
2019
Q3 		$94K Buy
+29,536
New +$111K 0.01% 1383
2019
Q2 		– Sell
-951
Closed -$7K – 3629
2019
Q1 		$7K Sell
951
-228
-19% -$1.6K ﹤0.01% 2849
2018
Q4 		$7K Buy
+1,179
New +$14.9K ﹤0.01% 2666

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Tower Research Capital (TRC)'s AQST Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Aquestive Therapeutics (AQST) stake by 8% in Q2 2026, buying an estimated $2.86K and bringing the position to 9,170 shares worth $38.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2965.

Tower Research Capital (TRC) first reported a position in AQST in Q4 2018 and has held it in 28 quarters since. The position peaked at $124K in Q1 2024. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Tower Research Capital (TRC) held 9,170 shares of Aquestive Therapeutics worth $38.1K as of Q2 2026.
  • Tower Research Capital (TRC) bought 679 Aquestive Therapeutics shares in Q2 2026, an estimated $2.86K.
  • Aquestive Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2965 holding.
  • Tower Research Capital (TRC) first reported a position in Aquestive Therapeutics in Q4 2018 and has held it in 28 quarters since.
  • Tower Research Capital (TRC)'s Aquestive Therapeutics position peaked at $124K in Q1 2024.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.